Publication | Closed Access

Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer

Lymphoid NeoplasiaCancer ImmunosurveillanceNon-small-cell Lung CancerMedicineImmunologyTumor ImmunityImmune Checkpoint InhibitorCancer TreatmentBaseline Pd-l1 ExpressionOncologyRadiation OncologyTumor MicroenvironmentLung CancerDurvalumab Consolidation Therapy